eli lilly up more than 300%. not as much for astrazeneca.although they did put up a good quarter of guidance, but over the last three years that stock underperforming. one area of potential growth in the future for these stocks be medicare advantage. right now it's not covered but the fda did approve will go ovi to improve the risk of heart attacks and stroke in overweight people and this could clear the path for approval from medicare for at least will go ovi and maybe the other loss drugs. take a look at the number of people this could bring to these drugs potentially in 2020 4 million people are expected to be enrolled in medicare advantage and the numbers only go in the right direction. let's take a look at those stocks in perspective once again here we have the s&p 500 and the health care index both higher over the last three years. take a look at eli lilly it is clearly the big winner, outperformance for some of these weight loss drugs. katie: that is a huge gap on the screen and feels like it's only getting bigger. for more on the wei

sounds like great show you've got lined up including the full interview with the ceo of eli lilly lastat 7:00 p.m. eastern time. look at the lineup when it comes to lilly and novo nordisk do they look full? >> no. they're just steadily order uptrends not straight up moonz moon shots novo nordisk, 94 to present, 30-year is 6 x that of lilly. >> 6 x. >> wow. >> it's interesting because we mentioned the data from novo nordisk, that was the flow study and they stopped it early. remember that time it shot up higher because of the initial release. this is the full data, and it didn't move. that's sort of telling in terms of how much had been factored into the stock before the final results. >> we've talked about it these are crowded trades, very few ways in which to play the people that have the supply right now and again, there's going to be so many other great uses for this. right now, there's only two ways to play. lilly broke out of a four-month consolidation and looks league >> sorry real quick, now if you look at the news last night in biotech you're starting to get some eyeballs on ca

--- a big investment from eli lilly nonetheless. joining us is clear harbor asset management co. founder -- co founder and ceo. you take a look at the week that was, tech is the only sector in the green out of 11. what does that say about when we might see this rally broaden out? we have been waiting and waiting. >> it's interesting, katie, to your point about tech, it is the only sector in the last five days that is in the green, and the overall s&p 500 as an example is down 30, the five bases point over that same time. when you look at tech as representing one third of the overall market, we have a little bit of a window into that. the broadening question is an important one. the russell 2000 is not up 2% on a year-to-date basis even though the s&p is up almost 12%. there is sensitivity around the state of the consumer as it pertains to the domestic nature of smaller cap names, the broadening of that market is probably going to require more confident for the consumers in good shape. keep in mind the small-cap part of the market is

both of those, reasons why we're seeing e eli lilly up eli lilly up 3%. >>> ether, what it might mean the rest of the crypto space as well. tamra, izzy, and emma... no one puts more love into logistics than these three. you need them. they need a retirement plan. work with principal so we can help you with a plan that's right for your team. let our expertise round out yours. >>> coming up next, we're less than an hour away from toll brothers results. we'll run you all the key erme is to watch out forn ovti. that and much more as we take you inside the market zone next. this is our future, ma. godaddy airo. creates a logo, website, even social posts... in minutes! -how? -a.i. (impressed) ay i like it! who wants to come see the future?! get your business online in minutes with godaddy airo so this is pickleball? it's basically tennis for babies, but for adults. it should be called wiffle tennis. pickle! yeah, aw! whoo! ♪♪ these guys are intense. we got nothing to worry about. with e*trade from morgan stanley, we're ready for whatever gets served up. dude, you gotta work on your trash ta

eli lilly, we just covered them.'s all summers form relation we should hear about very soon. this is not the dental, but it is the boyle company. so, we have oil, we have tech, because we know nvidia, obviously. united health, doesn't conflict with lilly? this is a drug insurer, and this is a health company, but they trade together in the health cohort, although, sometimes, when you trade on a hack, it is still different. what we are going to do is get rid of united health and i want to substitute a true industrial. the one i have my eye on is rtx, that was that merger with united states technologies. i have been working on it all weekend i think it is really good but getting away from it. that is what i suggest. next up, we have larry in oklahoma. larry? >> boo, yeah, jim. >> fired up, right? >> i think i have seen the movie "ted," too many times. >> that could be. >> here are my five stocks. >> microsoft, one strike, exxon, one oak, and apple. am i diversified? >> well, okay. now, we have to go back, microsoft is c

eli lilly up about 3.2% on the day. quayside technology among the biggest laggards. the maker of measurement equipment issued a forecast that disappointed wall street. some analysts see green shoots emerging from its communications a business. quayside down almost 10%. earlier today, we have to know one of wall street's most prominent bearers, morgan stanley chief u.s. equity strategist mike wilson hiked his s&p target about day ago. he spoke about his outlook. >> are housecall, it is a soft landing goldilocks outcome. we are not that confident we want to make it fully. it is still late cycle, which means quality. large caps over small caps. we like staples over discretionary. we have two defensive sectors overweight utilities and stables because it protects against slowing growth risk. the main factor that has been working his quality. quality has been the most consistent factor and we don't see that changing. sonali: we will discuss the market now and outlooks with bloomberg's opinion columnist who watches it closely. interesting to see what was wall street's bigge

and it's a window which novo nordisk and eli lilly argue. look, we develop these drugs, we should make some money in that period. we should benefit. i agree with them, but i would argue they don't need to make quite as much as they currently do. we could regulate them. you know, at the moment, novo nordisk is now the most profitable company in, the whole of europe. so i think we should be, you know, prioritizing, getting the drugs to people who need them, not least because by many measures, obesity is the killer in this country. professor mander at harvard, who the food label that's on all food the united states sold in the us. so explain to me, presented with his calculations that obesity and food related illnesses. kill 678,000 american boys every year that's more all the american soldiers who died in all the wars of the 20th century and indeed the war in this century and. i mean, that is a staggering toll. that's, you know, not far off having covid every year. the covid pandemic, every year. right. and that stock, we shouldn't accept this

and it's a window which novo nordisk and eli lilly argue. look, we develop these drugs, we should make some money in that period. we should benefit. i agree with them, but i would argue they don't need to make quite as much as they currently do. we could regulate them. you know, at the moment, novo nordisk is now the most profitable company in, the whole of europe. so i think we should be, you know, prioritizing, getting the drugs to people who need them, not least because by many measures, obesity is the killer in this country. professor mander at harvard, who the food label that's on all food the united states sold in the us. so explain to me, presented with his calculations that obesity and food related illnesses. kill 678,000 american boys every year that's more all the american soldiers who died in all the wars of the 20th century and indeed the war in this century and. i mean, that is a staggering toll. that's, you know, not far off having covid every year. the covid pandemic, every year. right. and that stock, we shouldn't accept this

eli lilly soaring more than 2.5% to close above $800 for the first time. company's glp-1 drug getting approval in china to treat type ii diabetes. the company also saw positive data in trials of its late-stage ch chrone's disease drug. so, a lot of developments here. obviously, for weight loss, we're still waiting for the approval for weight loss specifically, but it is regarded that this -- that's just going to be the next step. and then, of course, the supply issues still hold. >> the market continues to roar. then probably justifiably so, but you really got to believe in the -- basically in the revenue story, right? we had a whole conversation. who is the good-looking cat from cleveland, sits there with his little jacket on, talks about -- >> about lilly? oh, jared. >> yes, love him. i asked him the question, he said, they probably have runway. you don't need to see the type of revenue growth until 2026, and that's what the market is getting ahead of. if they show signs of not being able to get there, you know, again, this is a company that -- $158 bill

eli lilly has gotten a little extended. merck is trading at an all-time high. you get help from bristol myers at some point. and you have to love the space in general. >> it's interesting that you think eli lilly maybe from a valuation standpoint, guy, but really has been con sal dating over the last three months. we think about the guidance they just gave, and when you think about their glp-1 contribution to revenue growth, $18 billion on a $42 billion annual number or so, and it's still expected, total revenue base is growing 20% plus a year for the next couple years. so, again, if companies like roche are not going to have a real competitor for awhile, it seems like this is a very narrow trade, again, and sooner or later, another beat and raise and the stock is blowing out. it's going to have another gap higher. >> so, eli lilly and novo can protect that moat, because they have years before companies bring the product to market. but with the positive drug trial results, you get a reset. you get the markets thinking, they can be a contender that i are in the

>> we announced big partnerships with eli lilly and novartis. we are working on real drug programs.ould be expecting in the next couple of years the first ai designed drugs in the clinic. tom: that's really interesting. i know this is a passion of yours. you oversee this unit. it's a separate business under the bow -- alphabet family. you have those partnerships. novartis and eli lilly. up to $3 billion of revenue. does alpha fold three get you closer? >> yeah. it's a critical part of the tools we have at isomorphic. there's a lot of different techniques and modules that are needed in order to cover the whole of that very difficult process. alphafold2 is one small component of that. moving into things like biochemistry so we can design the right drug compounds. tom: are you under pressure to commercialize these products? what is the potential revenue stream of that? >> first and foremost, it's the most beneficial thing. the number one thing ai can do for humanity, solving hundreds of terrible diseases. i can't imagine a better use case for ai. that's partly the motivation behind iso

these are the ways that novo nordisk and eli lilly are finding ways to pay for the drugs.iver disease and kidney disease. that is why these drugs have a popular future. >> amgen is doing the first human trials and expected to have results in june i want to talk about something else regulation you are shaking your head. in the u.s., regulators accusing novo nordisk and a bunch of other drugmakers, to be fair, for having fake patented that won't hold up to scrutiny. how much of a risk is this >> it is typical for the ftc to put out a list of fake patent. the patents are massive. many patents covering them i think this is really just a bit of non-news. >> non-news? doesn't it raise the risks of generics entering the market which would reduce price and take market share? >> when a drug gets approved, there are lots of patents. typical patents are 100 to 150 covering formulation and how it works. those are not being challenged here i don't think this brings a risk of generics. that will come in the 2030s. we need to watch out for the long term. that is why the pipeline is impor

. >> my five stocks are amazon, honeywell, amd, microsoft, eli lilly. am i diversified?od question. we will let amazon be cloud computing. honeywell diversified manufacturer that we own for travel trust. eli lilly is probably to me the number one drug company in the world. this is what's important. microsoft and amd. we will have to make a choice. we will have to say we want to keep microsoft. we will have to go with amd. what we will do is why don't we put that in something i've been looking at all day. let's put in union pacific. that has come down far below where it should. a nice change for added transport. i think it will be a nice mix. i cannot believe we are done. we have such unbelievable portfolios. it makes you feel so great. thank you to everybody for saying it is a great thing. we've been doing it since 2001. >>> coming up, hit us with your best shot. and electrifying lightning round is next. at morgan stanley, old school hard work meets bold new thinking. to help you see untapped possibilities and relentlessly work with you to make them real. [♪♪] your skin

been up, and remember, amgen was up in january when they said this, and then we got the numbers and eli lillyto be doing really well. let lilly come down and buy a bundle. >> jim, let's get the opening bell here. at the big board, it is the consulate general of mexico in new york. cinco de mayo is this sunday. at the nasdaq, it's the committee to protect journalists. speak of amgen. that's going to be the lion's share of the dow. >>mgen is a great company, and bradway is a serious executive. they have an anti-cholesterol drug that's still not getting its due. they have a terrific migraine drug that is not getting its due. and all i can tell you is that they're a juggernaut that people don't think is a juggernaut, and their dow stock that everyone was unexcited about, but they and pfizer are the two drug stocks that are suddenly in the conversation again. and i think it's important to point out that pfizer may have some momentum too. >> yeah, huge weight in the dow, even before the jobs number was going to account for a couple hundred points of gain. >> sure, and obviously, the treasurys are s

they're rivals to eli lilly and -- lauren: weight loss drugs. they've got one.one of them. it's their weight loss pill. thought that would be so easy, right in take a pill -- stuart: yeah, a winner. lauren: are the trial data wasn't so good, so now they're doubling down on their weight loss shot. it's taken once a month, so less frequently, and it helps keep the weight off -- stuart: you've got that look on your face, bahnsen. >> we're huge shareholders of amgen. i don't think they've scrapped the weight loss bill -- pill, i think they're focus on the injection side. but there's not going to be an a duopoly here. eli lilly down quite a bit today, they've had the full run are on these weight loss pills. again, amgen still has to go to stage three, but they're moving forward to these clinical stus. stuart: the other two can't keep up with the demand -- lauren: supply can't keep up. stuart: amgen, they've got something going for them, who knows when, they can add to the supply. >> also a very promising on cog treatment as well, lungens cancer, is a really, really w

podemos ver que un 20% obtiene estas medicinas en un centro medico estetico o por por los laboratorios eli lillydisk reconocen que la fda tiene actualmente algunos de sus productos en la lista de escasez de medicamentos como disponibilidad limitada lo qu ha llevado a muchos a intentar conseguirlo sin supervision medica. >> esto ocho esto en ocho millones de personas han podido apreciar en varios paises del mundo lo que en ingles ingles se conoce como northern lights o en espanol moradas y hasta verdes que aparecen en el firmamento son producto de una perturbacion en el campo electromagnetico de la tierra debido a una tormenta geomagnetica severa por un aumento en la actividad solar. >> de hecho, los meteorologos espaciales de la noa emitieron una alerta de tormenta geomagnetica severa, la primera en casi 20 anos, advirtiendo al publico sobre los posibles efectos aqui en la tierra, como por ejemplo la afectacion de la red electrica, las comunicaciones por satelite y por radio de alta frecuencia, como son tambien los telefono celulares. >> y precisamente presidente joseph martinez, meteorologo de

eli lilly has great products a great name in the defensive health care space. >> like nvidia, but therethink it is overbought but you think there is more room to run? >> certainly more room to run. your prior guest talked about a.i. proliferation that can't be understated. hard to say things about nvidia that hasn't already been said. there might be improved supply chain to help get the chips out to market further. they take up in a stack necessarily in the data warehouses these days about 80% of compute space. that is only 15% just a mere five years ago. n sid -- nvidia has room to run because of that. they're in ongoing transition. data was a depository of files. people needed extra space to store extra files. now we're talking about serious computer power all things a.i., deep learning, data intensive computing tasks. a lot nvidia can offer. we like the name. we would stick with it. it is cash flow positive clearly and we have earnings report national about a week. ashley: we have another report tomorrow cpi, what are you expecting? if it comes in hotter than expected do we take a le

just minutes ago, eli lilly announced it's investing an additional $5.3 billion for its manufacturinge in indiana. that brings the company's total pledge to $9 billion. eli lilly says the new investment shows its commitment to meeting demands of megano and zeop, and both are used to treat type two diabetes and obesity. the company embarked on a manufacture expansion in 2020, driven by the research results for those drugs. and we know this has a big impact on a lot of you. a recent survey found that 1 in 8 american adults has taken a weight loss drug like those mentioned, and the demand has led to shortages. back to you. >> thanks, amanda. mechanical issue being blamed for diverting a united airlines flight headed to san francisco to denver yesterday morning. united didn't explain what the issue was, but says the flight from boston landed safely. 175 passengers and crew were able to get off the boeing 737 max nine and switch to another plane to continue the trip. you may remember the faa grounded boeing 737 max nine earlier this year after a door plug detached from an alaska airlines p

pfizer's announcement comes after another drug maker, eli lilly, launched a similar platform back injanuary. the new services come while drug makers are pushing to sell their products directly to consumers, rather than going through a pharmacy. there's a wave of disappointment and frustration for swimmers at acalanes high school tonight. they've learned they won't be able to swim in a critical swimming and diving championship this week. it appears their entries didn't get in in time, and a computer issue may be to blame, nbc bay area's christie smith explains. we're obviously feeling pretty bummed. kyle hansen sums up how some of the swimmers at acalanes high school are feeling with an important meet coming up that their team won't be able to compete in since it's out of our control and out of our reach and we're being penalized for it, so it's pretty devastating, especially since we had our freshman season taken away due due to covid. it's pretty bummed out for our senior season, taken away due to this too. this is like our biggest meet besides state championships in the whole entir

eli lilly shares getting a 52-week high after the drug maker in with a boston-based startup to deliverp 2.8%. commerzbank getting highs earlier after morgan stanley raised its target to 20 euros. stay tuned to that one. we have burberry hitting a 52 week low after barclays lowered its price target on the stock, remaining cautious in the short-term. shares have fallen over 10% since it reported earnings last week with a week forecast. you can see shares down about 3.8% over the last two days. coming up on bloomberg technology, the cfo of zoom joins caroline hyde. that does it for bloomberg markets. i'm katie greifeld and this is bloomberg. ♪ what about zocdoc? so many options. yeah, and dr. xichun even takes your sketchy insurance. xi-chun, xi-chun, xi-chun! you've got more options than you know. book now. >> this is bloomberg technology with caroline hyde and ed ludlow. ♪ caroline: i am caroline hyde in new york. ed ludlow is off. coming up, baseless of reportingtsmc and asml down the keyq

as the washington post points out companies are removing all references to de i including calls eli lilly starbucks and coors and americans just want to be or not a lecture to come with it especially if the broad doing the finger way also wags a penis. whether students know it or not the trend would help them because they won't hire the enemy nobody wants to hire a fresh columbia log read just as you wouldn't throw a live grenade into your own bear acts was nice to know you were hired for your talent experience and skill not because you look like a plus sized model from appellate on add and it's great news is the hiring pool just got deeper and wider then stormy daniels lies. you cannot worry about hiring a brainwashed marxist who believes 2 plus 2 equals racist. [ cheers and applause ] i can rest. but there are holdouts 1 group they think moving the letters de i around will do the trick they replaced the term with ied. what's that normally stand for improvised explosive device great marketing guys. i guess std was already taken. but it's actually closer to the truth than they realized le

this actually comes in line from eli lilly earlier this week and they increased guidance for the yearnd that goes to show the demand is strong a final point when we heard from the ceo in early march, he sai the gap between supply and demand is significant and that the company is not going to be able to fulfill that in the next couple of years. despite price pressure, despite conversations around litigation stateside as well, when you think about the outlook and demand for the drugs that is still very strong and, therefore, it is seen by the bulls as a way or opportunity to buy here, frank. >> despite a blowout quarter, novo nordisk shares down 3%. silvia, thank you very much. >>> we will move on to shell it posted $7.7 billion in profit for the first quarter. the energy giant announcing a $3.5 billion buyback program set to take place in the next three mo months shares up 1.5% >>> maersk raised the outlook after beating first quarter revenue estimates. it sees the trend to the higher end of the guidance. the company says there has been significant disruption since the start of the yea

will see large overweights relative to what you would find in a traditional index, like names like eli lillyvex. these are game-changing drugs, and the traditional means of getting into them, it doesn't do justice to the exposure needed >> i think it has been slow launching these considering they have been out for over a year. there are 20 companies in the eft, and i will not go through all of them, but 40% for two companies, and novo is up and lilly is up, and how much room is there we seem to be coming a little bit after the first crest? >> yeah, like when we saw the ai wave, and people said it's an ai bubble and it's over, and what is exciting is there's more companies coming, right? right now they are injectables, and there are companies working on oral therapeutics, and they are even more powerful >> we will talk about all of them coming up but you had a big hit last year, the big eft hit, mags, it came out of nowhere, and you will have a concentrated bet on china this time, and this consists of eight china, alibaba, jd.com -- why are you making a concentrated bet on china right now? i

amgen is planning a late stage rally for treatment against novo nordisk and eli lilly. >>> coming up,really grinds its gears. why jim cramer says people are focused too much on the anfed d not corporate earnings. we'll be right back after this break. lity solutions. because sometimes the best road forward, is the one you didn't expect. (♪♪) (grandpa vo) i'm the richest guy in the world. hi baby! (woman 1 vo) i have inherited the best traditions. (woman 2 vo) i have a great boss... it's me. (man 1 vo) i have people, people i can count on. (man 2 vo) i have time to give (grandma vo) and a million stories to share. (grandpa vo) if that's not rich, i don't know what is. (vo) the key to being rich is knowing what counts. i don't want you to move. i'm gonna miss you so much. you realize we'll have internet waiting for us at the new place, right? oh, we know. we just like making a scene. transferring your services has never been easier. get connected on the day of your move with the xfinity app. can i sleep over at your new place? can katie sleep over tonight? sure, honey! this generation is

regulators for a late stage trial and possibly entry into the market is sending major players like eli lillyker of zepbound down 1.2% and novo nordisk maker of wegovy down half a percent. in the last few months, gyms have warned they're seeing lower attendance, wal-mart said its customers on ozempic are buying less oturu grocery stores and gnc wants to capitalize on the shifts and the nutrition company launched a new strategy to cater to gl1 users and a wall of supplements in their stores with 200 products that they believe will appeal to those on the drugs. ceo michael costello joining us live from the gnc store in derby, kansas. michael, how are you evolving retail stores in space and more. >> they've been helping consumers live well and gnc is a new trend and lots of side effects and 15% of people leave the treatment because of side effects, especially with gi issues. liz: okay and talk about the side effects. there's fatigue, nutrient deficiency and loss of muscle and what products do you have and why you're changing your shelving to make an entire area. i assume you see demand here. >>

cutting the price of its weight loss drug wegovy, in a response to higher competition from us rival eli lillyd quarterly revenue from the blockbusterjab. however the company said has boostedsales volumes and the drug is now being prescribed to 25,000 new patients in the us per week, compared with 5,000 in december. the uk—based energy giant shell has reported a profit of $7.7 billion for the first three months of the year thanks to a strong performance at the training and... the uk based energy giant shell has reported a profit of $7.7 billion for the first three months of this year thanks to a strong performance from its oil trading and refining divisons. the company says it will use the better than expected profit to return $3.5 billion to shareholders. that could help increase the value of the company at a time when its microsoft's chief executive, satya nadella, is on the final stop of his trip to southeast asia. he is in malaysia, where he announced a $2.2 billion ai and cloud investment in the country. mr nadella was in indonesia and thailand earlier this week. he met officials and busi

we saw yesterday eli lilly missed on mounjaro. but they raised guidance and said they were feeling much more confident in supply. even if nor voevo were to miss >> also some very interesting news from u.s. regulators, challenging some of their patents for ozempic. changing the drug in the one space and calling them junk patents. you laughed. it sounds like you disagree. you've seen aggressiveness in theattack. how possible is it the patent will be taken away and taking away market share>>> i think the ip landscape in the u.s., the battle between the companies and regulators has been going on for quite some time. i think we're feeling very comfortable that the first patents on ozempic will be in the early part of the next de decade. but one thing that's unique about the obesity market, the numbers are so big, we're thinking that the scale is going to be tough for generics to really displace the brands in a big way. novo is kind of unique in that regard. >> it's interesting that you say that. when it comes to the weight loss drugs,

the company is emerging as a potential competitor to eli lilly and novo nordisk -- did a sports car atfor over a $400,000 inspired by cars from the 1960's and was unveiled yesterday in miami ahead of the formula one grand prix happening this weekend. monster beverage reporting first quarter better than investors feared but not fully easing fears and the drink market in the u.s. they also plan to raise prices in the fourth quarter. you can follow the latest company bus on your bloomberg terminal. coming up, an exclusive interview with the president of the chicago fed jason robins -- fed, austan goolsbee. that is coming up. ♪ that your customers need to know about. constant contact makes it easy. with everything from managing your social posts, and events, to email and sms marketing. constant contact delivers all the tools you need to help your business grow. get started today at constantcontact.com constant contact. helping the small stand tall. >> welcome to the campus of stanford university, the military policy conference. we are excited to have with us austan goolsbee, the president

i will give you four, nvidia, abercrombie & fitch, gap stores or lily, eli lilly with the great myrle you want to be buying in this market. by the way he is still bullish but extremely selective. we'll be right back. >> has it been 10 years? oh, yes it has, of "making money" and lots of it, charles payne. >> making america rich again, charles payne. congratulations on 10 years. >> indeed. (vo) what does it mean to be rich? maybe rich is less about reaching a magic number... and more about discovering magic. rich is being able to keep your loved ones close. and also send them away. rich is living life your way. and having someone who can help you get there. the key to being rich is knowing what counts. her uncle's unhappy. i'm sensing an underlying issue. it's t-mobile. it started when we tried to get him under a new plan. but they they unexpectedly unraveled their “price lock” guarantee. which has made him, a bit... unruly. you called yourself the “un-carrier”. you sing about “price lock” on those commercials. “the price lock, the price lock...” so, if you could change the price, cha

. >> the other thing to watch for in pharma, so much has gone to eli lilly and to novo. if some other companies can execute, you get a lot more capital at a much cheaper valuation. it's going to become that big four, the big two in pharma. if some of the others can execute, you'll see some cap. >> they have been going to glp-1. hard for anything else to raise its hand, hey, take a look at us. we're developing some potentially life-changing drugs as well, but that's where the story has been. >> and it used to be you get credited phase 2 coming into phase 3. now you don't get credited until the approval. >> the risk curve -- >> a big pain medicine that could be huge. >> you want to buy it now if it happens not when it gets approved. >> farmer jim, you sold reit, camden property trust. >> it's my only reit. i'm not too enthusiastic about reits. camden property is an apartment reit. i hate having intellectual conflicts. we're sitting here hoping for inflation to come down and one of the major components that will make that happen is apartment rents coming down. i can't be ho

eli lilly you think could be one. >> that's right. a lot of these names, whether it's health care or consumer discretionary, companies that are very visible to investors and consumers are poised to benefit the most as you mentioned, the history on this is compelling, that the average stock after a share split, returns about 25% over the subsequent year in our historical data. if you compare that to about 12%, it looks like an interesting trade opportunity when companies decide to send that shareholder friendly signal >> you have super micro, lam research they also get an added lift when the spoke split usher them into an index like the dow, or some of the smaller ones you don't get as much of a benefit but is there a boost to names that might split and enter the blue chips >> it can be, it can be the case and whether it's in the dow or the s&p 500, or however investors hear about the news, i think that, again, it's more about perception than fundamentals and when investors have so many ways to invest today, etfs, different funds, bond

s&p 500, dollar general, eli lilly, first solar, seize or star's entertainment and moog.la at the top there, up 2 this morning. dollar tree, lam research, astrazeneca too. the 10-year treasury yield with, always a important, right now it's right at 4.40%. way below $4.5. price of gold with, $2,455, down about $5 today. bitcoin, as we've been telling you, rallying. $70,900 right now. it was $72 to ,000. oil down despite a what's happening in the middle east. oil's down, $78 a barrel. nat gas, $269. gasoline, as in regular, the average around the country is $3.59 a gallon. diesel, it's actually up one cent at $3.90. >>> coming up, president biden wants to flip the narrative on inflation. he's putting the blame on corporate greed. will voters buy that? we're on it. >>> a new cruise line are offering retirees the chance to live full time on its ship, travel the world. why not? we've got the company's chief executive on the show. i'd love details on that. >>> fdic chair martin greenberg announced he's stepping down after the elite of a scathing -- release of a scathing report

it has the business best model in pharma and it's not eli lilly. he's here to make his case and michael santoli kicks things off at the new york stock exchange >> hi, kelly we have steady indexes here which means that the s&p 500 is holding on to last week's gains and holding on to this little 5% rebound rally we've had over the prior three weeks and to me, the story of the market, this latest pace started six weeks ago at the all-time highs and that was the last trading day of the quarter and to me it was the moment of maximum confidence in the scenario and it was right after the fed sort of confirmed the expectation of three rate cuts in the dot plot about a week before. the first quarter gdp was looking great. earnings anticipation was running high so i think that we've had tests on both those fronts and obviously, a third, straight, hot month of inflation readings and we had a question about the fed path and treasury yields go back to six-month highs and all of it created what looks for the moment as a normal, 5% pullback and the rebound rally

joined tonight, we've got roger penske, the governor of indiana, the ceo of pnc, and the ceo of eli lillyably some surprises. that's tonight >> that's a great lineup thank you so much. looking forward to watching that appreciate you with that interview today. >>> summer is heating up so is our stock draft. carvana has surged, and we will have more on oz pearlman and you can catch the podcast, listen and follow, final "power lunch" on any of your favorite platforms. we'll be right back. ga, the advanced form of dry age-related macular degeneration, can irreversibly damage your vision. it can progress faster than you think. when ga threatens your eyes, take a stand. slow ga with syfovre. syfovre is an eye injection that was proven to slow damaging lesion growth over 2 years with increasing effect over time. it's the only fda-approved treatment to slow ga in as few as 6 doses per year. don't take syfovre if you have an infection, or active swelling in or around your eye that may include pain and redness. syfovre can cause serious side effects, such as eye infection and retinal detachments, s

it would be an injection, and it's one of the reasons why eli lilly and novo nordisk is down -- are down. if amgen up almost 13%. stuart: how about estee lauder? lauren: down 10% this week, they gave a weak second half outlook, and they got a downgrade today at morgan stanley. they go to neutral. stuart: williams-sonoma a? lauren: upgrade to neutral with a price target of 27. 5 -- stuart: wait a minute, it's at 304 -- lauren: yeah. their commentary was good, will. yams sonoma is the home of picety spatulas, i always go for mid salad tongs. they're more money, but they work. if you look at the home furnishings category, in general it's improving especially out west. stuart: stock's up 4%, $300 a share. all right, take it. >>> coming up, a new report ea veal ises billions of dollars from mideastern countries have gone towards temperature funding our colleges. is that what's helping fuel the anti-semitech and anti-american protests? we're going to dig into it nor you. >>> trump is hosting a republican donor event in palm beach this weekend. a number of his potential vice presidential picks

look at eli lilly, they had their factories running 24/7.vo nor dissing has more competition and lower prices. stuart: okay. thanks, lauren. so we're into this market six minutes, that's are where we are, it's i 9:36. adam's with us with stock picks. >> oh, there she is, chub. love it. yeah, this is the best run insurance company. i mean, it's really the rolls royce of insurance. you say, yeah, but adam, i thought you were the american ingenue ifty guy, right? they do a brilliant job at a running this business. they have the most efficient, lowest combined ratio in the business, trading only about 12 times earnings right now. it's cheap. historically trades at 16 times. it's growing 8-10%. it's a function of interest rates because that's the big question, and what does that do for the profits? don't worry about it, just buy it. it's making new highs and it'll continue to make new highs. stuart: you also like nvidia. it's under 8550, you like -- >> well, it went down into the 7000s. you know, at one point -- 700s, we hadn't talked about it fo

eli lilly happens to be our number one pharmaceutical holding. mounjaro, the glp-1 drug they have.vid line, but it's still a covid play, or old news. i'd rather be in something fresh. stuart fourth stock never does very much, does it? >> pays a decent dividend. stuart: cvs, it's tumbling, down 17%. that's a 4-year low. they slashed their full-year outlook. they say soaring medical costs in the insurance unit. i don't think they said anything about shoplifting and shrinkage, and i think that might be a factor at cvs. >> that's a great point. one of the key things that a cvs or a walgreens does is they get people to come in for their medications. now, cvs is having ab issue with medicare advantage, it's really beating them up from a cost standpoint, or but you get e people to come in and pick up their medications and and then get them to buy an overpriced snicker bar or whatever it might be. they're all a locked up. you can't get to 'em. [laughter] so the things where they generate the majority of their profits, it is no longer frictionless for a consumer to pick up a snicker bar and

and the manufacturers of these drugs, novo nordisk and eli lilly have actually been struggling to keeph demand. so presumably even more people would be on these medications if the companies could make more and they are desperately trying to ramp up the manufacturing now among the people who report ever taking one of these medications, folks with diabetes, we're most likely to have said they've taken one more than 40% among people with heart disease, 26% said they taken one of these drugs and among people whose doctor said they had obesity or overweight, 22% said they had ever taken one. now affordability of these medications is huge problem in the united states. they cost more than $1,000 out of pocket each month without insurance and insurance coverage can be really difficult in this poll. more than half say that these medicines have been difficult to afford even with insurance. and 22% say they'd been very difficult one group that's had a special trouble with this has been people over the age of 65 who may be covered by medicare because medicare can't cover drugs that are approved ju

eli lilly launched a similar website earlier this year.imes reports that pfizer's site is expected to launch in the coming months. well, the song is over for twin brothers. this is on. they are from the peninsula and came up just short of that major accomplishment. so the twins were just eliminated on nbc's the voice. but as far as we're concerned, they are still winners. watch the sunset over, over the castle on the hill. jeremy and justin garcia performed for the last time monday night, singing columbus castle on the hill. they lost in the playoff round. we did catch up with them. fresh off their reign as members of team reba, and they say their brotherly bond helped during the competition. we really just try to communicate what was best for the both of us and what our strengths were, to kind of fit in with with the song that we were singing, and we really wanted to highlight both of what we could do, for each performance. as for the future, jeremy says he's received a full ride to uc berkeley, where he plans to focus on production. just

washington post points ouwht, a lot of companies are removing all references to dea by including coles, eli lilly, starbucks and coorncludings. and as anheuser-busch has learned, americans just wantto a beer, not a lecture to come with it, especially if the broa espd, the finger waggig also wags a and whether students know it or not, this trend is going to help them because companies won't hire the enemy. no one wants to hire a fresh en law grad bathed in deep hate, just as you wouldn't throw a live intoade io your own barracks. plus, it's nice to know that you were hired for your talent, experience and skill. not because you lookt experiencs size model from a benetton ad and it's great news forws is companies. the hiring pool just got deepetr and than stormy daniels lies. stormy daniels lies. you can now hire the most competent applicant, not worry y and not worry about hiring a brainwashed who thinksa two plus two equals racist. >>rxist wh there are. okay, i can rest, but there are holdouts. one group, the society for human resource management, thinks just moving letters d-ier around will do th

and the manufacturers of these drugs novo nordisk eli lilly, has actually been struggling to keep up with demand so presumably, even more people would be on these medications if the companies could make more and they are desperately trying to ramp up the manufacturing. now among the people who report ever taking one of these medications, folks with diabetes, we're most likely to have said they've taken one more than 40% among people with heart disease, 26% said they'd taken one of these drugs. and among people whose doctor said they had obesity or overweight, 22% said they had ever taken one. now, affordability of these medications is a huge problem in the united states. they cost more than $1,000 out of pocket each month without insurance and insurance coverage can be really difficult in this poll, more than half, say that these medicines have been difficult to afford even with insurance. and 22% say they'd been very difficult. one group that's had a special trouble with this has been people over the age of 65 who may be covered by medicare because medicare get cover drugs that are

the companies that make them novo nordisk and eli lilly, they cannot make enough to satisfy demand.o we're talking about these glp-1 receptor agonist drugs, including ozempic, mounjaro, which are approved for type two diabetes and wegovy and zepbound which are approved for weight loss. now this new poll from kff shows that 12% of americans in this poll, one out of eight people says they've ever taken one of these drugs, 6% say they are currently taking one that equates to about 15 million americans. and there would be more if there wasn't a shortage. so keep that in mind. >> now, among people with type two diabetes, those are the most common folks to have said that they've ever taken one of these medicines more than 40%, about 26% of people with heart disease say they've ever taken one of these drugs and 22% of people with obesity or who are overweight so, of course we know that there is a clamoring for these medicines. >> the companies can't make enough and these numbers are only expected to keep rising it's not cheap. >> i mean, what are the polls say about the cost right now of t